The efficacy of the combination of venetoclax and hypomethylating agents versus HAG agents in patients with acute myeloid leukemia: a retrospective study

Objectives: The purpose of this study was to compare the effectiveness of the combination of venetoclax and hypomethylating agents with the HAG regimen.Methods: We studied 52 cases of newly diagnosed AML and 26 cases of relapsed refractory AML, (including AML patients with treatment-related and ELN-...

Full description

Saved in:
Bibliographic Details
Main Authors: Fei Xin, Yan-Hui Yu, Xu-Liang Shen, Guo-Xiang Zhang
Format: Article
Language:English
Published: Taylor & Francis Group 2024-12-01
Series:Hematology
Subjects:
Online Access:https://www.tandfonline.com/doi/10.1080/16078454.2024.2350319
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1846126625254539264
author Fei Xin
Yan-Hui Yu
Xu-Liang Shen
Guo-Xiang Zhang
author_facet Fei Xin
Yan-Hui Yu
Xu-Liang Shen
Guo-Xiang Zhang
author_sort Fei Xin
collection DOAJ
description Objectives: The purpose of this study was to compare the effectiveness of the combination of venetoclax and hypomethylating agents with the HAG regimen.Methods: We studied 52 cases of newly diagnosed AML and 26 cases of relapsed refractory AML, (including AML patients with treatment-related and ELN-adverse risk disease (n = 50)). These patients were treated with venetoclax and hypomethylating agents and HAG regimens, respectively.Results: Twenty-nine patients newly diagnosed with acute myeloid leukemia were treated with VEN-HMA (venetoclax-hypomethylating agent), while 23 patients were treated with HAG. The median age of the VEN-HMA group was 70 years, while the HAG group had a median age of 69 years. The VEN-HMA group achieved a significantly higher rate of complete remission (82.7%) compared to the cohort treated with the HAG regimen (21.7%) (P < 0.001). At the same time, the VEN-HMA group exhibited a significant survival advantage compared to the HAG treatment group(HR = 0.328, 95%CI: 0.158-0.683, P = 0.003).In patients with relapsed and refractory acute myeloid leukaemia, 43.8% of patients in the VEN-HMA treatment group achieved complete remission, which was similar to the 50% in the HAG treatment group (P > 0.99). The median overall survival was similar between the VEN-HMA and HAG groups, with 4 and 3.67 months, respectively (P = 0.290).Conclusions: In conclusion, our analyses indicated that VEN-HMA resulted in better therapeutic outcomes compared to HAG for newly diagnosed AML patients, with higher rates of complete remission and overall survival. In relapsed/refractory AML patients, there was no significant difference in the efficacy of the two treatments and further studies with larger sample sizes are warranted.
format Article
id doaj-art-0fab1d27c82c44a88981bded59d4a223
institution Kabale University
issn 1607-8454
language English
publishDate 2024-12-01
publisher Taylor & Francis Group
record_format Article
series Hematology
spelling doaj-art-0fab1d27c82c44a88981bded59d4a2232024-12-12T15:08:53ZengTaylor & Francis GroupHematology1607-84542024-12-0129110.1080/16078454.2024.2350319The efficacy of the combination of venetoclax and hypomethylating agents versus HAG agents in patients with acute myeloid leukemia: a retrospective studyFei Xin0Yan-Hui Yu1Xu-Liang Shen2Guo-Xiang Zhang3Department of Hematology, Heping Hospital Affiliated to Changzhi Medical College, Changzhi, People’s Republic of ChinaDepartment of Hematology, Heping Hospital Affiliated to Changzhi Medical College, Changzhi, People’s Republic of ChinaDepartment of Hematology, Heping Hospital Affiliated to Changzhi Medical College, Changzhi, People’s Republic of ChinaDepartment of Hematology, Heping Hospital Affiliated to Changzhi Medical College, Changzhi, People’s Republic of ChinaObjectives: The purpose of this study was to compare the effectiveness of the combination of venetoclax and hypomethylating agents with the HAG regimen.Methods: We studied 52 cases of newly diagnosed AML and 26 cases of relapsed refractory AML, (including AML patients with treatment-related and ELN-adverse risk disease (n = 50)). These patients were treated with venetoclax and hypomethylating agents and HAG regimens, respectively.Results: Twenty-nine patients newly diagnosed with acute myeloid leukemia were treated with VEN-HMA (venetoclax-hypomethylating agent), while 23 patients were treated with HAG. The median age of the VEN-HMA group was 70 years, while the HAG group had a median age of 69 years. The VEN-HMA group achieved a significantly higher rate of complete remission (82.7%) compared to the cohort treated with the HAG regimen (21.7%) (P < 0.001). At the same time, the VEN-HMA group exhibited a significant survival advantage compared to the HAG treatment group(HR = 0.328, 95%CI: 0.158-0.683, P = 0.003).In patients with relapsed and refractory acute myeloid leukaemia, 43.8% of patients in the VEN-HMA treatment group achieved complete remission, which was similar to the 50% in the HAG treatment group (P > 0.99). The median overall survival was similar between the VEN-HMA and HAG groups, with 4 and 3.67 months, respectively (P = 0.290).Conclusions: In conclusion, our analyses indicated that VEN-HMA resulted in better therapeutic outcomes compared to HAG for newly diagnosed AML patients, with higher rates of complete remission and overall survival. In relapsed/refractory AML patients, there was no significant difference in the efficacy of the two treatments and further studies with larger sample sizes are warranted.https://www.tandfonline.com/doi/10.1080/16078454.2024.2350319Acute myeloid leukemiavenetoclaxHAG regimencomplete remissionoverall survivalnewly diagnosed
spellingShingle Fei Xin
Yan-Hui Yu
Xu-Liang Shen
Guo-Xiang Zhang
The efficacy of the combination of venetoclax and hypomethylating agents versus HAG agents in patients with acute myeloid leukemia: a retrospective study
Hematology
Acute myeloid leukemia
venetoclax
HAG regimen
complete remission
overall survival
newly diagnosed
title The efficacy of the combination of venetoclax and hypomethylating agents versus HAG agents in patients with acute myeloid leukemia: a retrospective study
title_full The efficacy of the combination of venetoclax and hypomethylating agents versus HAG agents in patients with acute myeloid leukemia: a retrospective study
title_fullStr The efficacy of the combination of venetoclax and hypomethylating agents versus HAG agents in patients with acute myeloid leukemia: a retrospective study
title_full_unstemmed The efficacy of the combination of venetoclax and hypomethylating agents versus HAG agents in patients with acute myeloid leukemia: a retrospective study
title_short The efficacy of the combination of venetoclax and hypomethylating agents versus HAG agents in patients with acute myeloid leukemia: a retrospective study
title_sort efficacy of the combination of venetoclax and hypomethylating agents versus hag agents in patients with acute myeloid leukemia a retrospective study
topic Acute myeloid leukemia
venetoclax
HAG regimen
complete remission
overall survival
newly diagnosed
url https://www.tandfonline.com/doi/10.1080/16078454.2024.2350319
work_keys_str_mv AT feixin theefficacyofthecombinationofvenetoclaxandhypomethylatingagentsversushagagentsinpatientswithacutemyeloidleukemiaaretrospectivestudy
AT yanhuiyu theefficacyofthecombinationofvenetoclaxandhypomethylatingagentsversushagagentsinpatientswithacutemyeloidleukemiaaretrospectivestudy
AT xuliangshen theefficacyofthecombinationofvenetoclaxandhypomethylatingagentsversushagagentsinpatientswithacutemyeloidleukemiaaretrospectivestudy
AT guoxiangzhang theefficacyofthecombinationofvenetoclaxandhypomethylatingagentsversushagagentsinpatientswithacutemyeloidleukemiaaretrospectivestudy
AT feixin efficacyofthecombinationofvenetoclaxandhypomethylatingagentsversushagagentsinpatientswithacutemyeloidleukemiaaretrospectivestudy
AT yanhuiyu efficacyofthecombinationofvenetoclaxandhypomethylatingagentsversushagagentsinpatientswithacutemyeloidleukemiaaretrospectivestudy
AT xuliangshen efficacyofthecombinationofvenetoclaxandhypomethylatingagentsversushagagentsinpatientswithacutemyeloidleukemiaaretrospectivestudy
AT guoxiangzhang efficacyofthecombinationofvenetoclaxandhypomethylatingagentsversushagagentsinpatientswithacutemyeloidleukemiaaretrospectivestudy